Stock listing

NASDAQ:NRSN NeuroSense Therapeutics Ltd. Stock

Home listing (NASDAQ) of NeuroSense Therapeutics Ltd.

Follow NeuroSense Therapeutics Ltd. into a list and get an email when it puts out news.

Share price · NASDAQ:NRSN

$1.28 USD -0.09 (-6.6%)

Close on Nov 20, 2026

Past year -94.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.27 – $1.34 USDNov 20, 2026
Volume
9,960 sharesNov 20, 2026
Market cap
$2.43M USDAt the close on Nov 20, 2026 · price × 1.90M shares outstanding
52-week range
$1.10 – $24.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$75,165 USDMedian day 13,848 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
NeuroSense Therapeutics Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NRSN · Home$1.28 USD-0.09 (-6.6%)9,960$1.32$1.343$1.27$1.37Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRSN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.28-0.09-6.6%$1.32$1.343$1.279,960
$1.37-0.14-9.3%$1.58$1.58$1.3314,600
$1.51-0.055-3.5%$1.54$1.61$1.49511,971
$1.565-0.125-7.4%$1.69$1.69$1.529,354
$1.69-0.07-4.0%$1.72$1.78$1.5918,304
$1.76-0.02-1.1%$1.816$1.83$1.7329,640
$1.78-0.20-10.1%$1.98$2.17$1.7051,943
$1.98+0.12+6.5%$1.85$2.01$1.6048,951
$1.86+0.18+10.7%$1.74$1.87$1.6038,512
$1.68+0.285+20.4%$1.47$1.68$1.3017,313
$1.395-0.025-1.8%$1.50$1.59$1.3451,320
$1.42+0.14+10.9%$1.28$1.45$1.2824,529
$1.28-0.15-10.5%$1.40$1.46$1.2025,037
$1.43-0.56-28.1%$2.02$2.04$1.10407,490
$1.99-0.14-6.6%$2.20$2.22$1.9920,177
$2.13-0.23-9.7%$2.302$2.32$2.0920,577
$2.36-0.01-0.4%$2.33$2.37$2.2017,301
$2.37+0.04+1.7%$2.30$2.60$2.2822,274
$2.33-0.13-5.3%$2.466$2.75$2.3129,709
$2.46+0.02+0.8%$2.49$2.55$2.4011,153
$2.44-0.12-4.7%$2.55$2.57$2.1518,597
$2.56+0.17+7.1%$2.46$2.70$2.4111,270
$2.39-0.275-10.3%$2.74$2.74$2.1913,848
$2.665-0.405-13.2%$2.94$2.94$2.359117,602
$3.07-0.10-3.2%$3.06$3.24$3.069,704
$3.17+0.11+3.6%$3.08$3.261$2.8711,863
$3.06-0.43-12.3%$3.56$3.60$3.0530,844
$3.49+0.01+0.3%$3.774$3.784$3.36543,216
$3.48-0.18-4.9%$3.66$3.66$3.287,424
$3.66+0.08+2.2%$3.614$3.85$3.61415,607
$3.58-0.24-6.3%$3.82$3.898$3.56115,850
$3.82-0.25-6.1%$3.95$4.07$3.7912,891
$4.07+0.04+1.0%$4.03$4.33$3.9417,784
$4.03+0.095+2.4%$4.06$4.54$3.9612,245
$3.935-0.115-2.8%$3.97$4.01$3.8224,230
$4.05-0.38-8.6%$4.37$4.37$3.82751,913
$4.43-0.35-7.3%$4.71$4.743$4.0040,386
$4.78-0.32-6.3%$5.04$5.54$4.35535,864
$5.10-1.85-26.6%$6.91$7.15$4.92561,785
$6.95-0.45-6.1%$7.18$7.18$6.7338,674
$7.400.000.0%$7.20$7.40$6.9258,879
$7.40+0.22+3.1%$7.35$7.40$6.808,761
$7.18+0.56+8.5%$6.70$7.41$6.7028,550
$6.62+0.27+4.3%$6.42$6.85$6.406,385
$6.35-0.37-5.5%$6.99$6.99$6.357,377
$6.72+0.23+3.5%$6.35$6.95$6.3013,680
$6.49-0.54-7.7%$7.04$7.50$6.0224,763
$7.03+0.13+1.9%$6.43$7.29$6.05542,311
$6.90-0.06-0.9%$6.80$7.46$5.6031,299
$6.96+0.32+4.8%$6.92$7.00$6.60569
$6.64-1.40-17.4%$7.60$7.76$6.641,721
$8.04-0.32-3.8%$8.64$9.00$7.96850
$8.36-1.88-18.4%$10.20$10.36$7.202,558
$10.24+2.20+27.4%$8.00$10.52$7.2010,561
$8.04-0.20-2.4%$9.00$9.00$8.00211
$8.24-0.16-1.9%$8.36$9.00$7.80530
$8.40-0.16-1.9%$8.68$9.00$8.20198
$8.56+0.16+1.9%$9.00$9.00$8.12418
$8.40-0.40-4.5%$8.80$9.00$8.40238
$8.80+0.60+7.3%$8.04$8.80$8.00147
$8.20+0.56+7.3%$8.20$8.80$7.80510
$7.64+0.12+1.6%$7.80$8.40$7.40478
$7.520.000.0%$7.60$7.60$7.24406
$7.52+0.52+7.4%$7.28$7.80$7.04321
$7.00-0.96-12.1%$8.00$8.00$6.96851

Splits

1 split · NASDAQ:NRSN · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
Ticker
NASDAQ:NRSN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All NeuroSense Therapeutics Ltd. news

NeuroSense Therapeutics Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 137 in all · newest Nov 2, 2026 · oldest 2021
Decks
18 decks · latest July 2026

Where NeuroSense Therapeutics Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:NRSN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:NRSNBOATSUnited StatesUSD
Frankfurt:H1ZFrankfurtGermanyEUR

Valuation

Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$2.20M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
1.41

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
BioAtla, Inc. · NASDAQ:BCABUS$2.58MUS$2.01Mn/an/an/an/an/an/a-0.34
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Median of the othersUS$2.40MUS$1.58M0.7×20.1×0.4×−63.4%0.1×1.01

Forecasts

1 strong buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
91.75 USD · Analysts' mean
EPS, year to Dec 2026
-3.88 · 2 analysts

Team and board

Officers

OfficerRole
Alon Ben-NoonCEO & Board Member
Or EisenbergChief Financial Officer
Shiran ZimriVP R&D | Country Lead, Canada
Hagit BinderGeneral Manager
Niva Russek-BlumChief Technology Officer

Board

DirectorRole
Mark LeuchtenbergerChairman of the board
Alon Ben-NoonCEO & Board Member
Cary ClaiborneBoard Member
Christine PellizzariBoard Member
Revital Mandil-LevinBoard Member
Roy GolanBoard Member

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Jun 30, 2026+2.0%
Q4 2025Mar 25, 2026+5.5%
Q3 2025Nov 26, 2025+14.4%
Q2 2025Aug 1, 2025−30.0%
Q1 2025Apr 7, 2025 · After close−2.3%
Q3 2024Dec 18, 2024 · Before open+4.6%
Q2 2024Sep 30, 2024 · After close−3.9%
Q1 2024Jun 24, 2024 · Before open−5.8%
Q4 2023Mar 29, 2024 · Before open+0.6%
Q3 2023Nov 28, 2023 · Before open+6.0%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 16, 2023 · After close−3.3%
Q1 2023Jun 1, 2023 · Before open+0.6%
Q4 2022Mar 22, 2023 · Before open−4.6%
Q3 2022Dec 1, 2022 · Before open−1.2%
Q2 2022Aug 31, 2022 · Before open−2.0%
Q1 2022May 31, 2022 · Before open−5.4%
Q4 2021Mar 2, 2022+3.8%
Q3 2021Dec 10, 2021 · Before open−20.5%
Quarter to Mar 31, 2021Jun 30, 2021
Quarter to Dec 31, 2020Mar 31, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck32 slidesJuly 2026
Investor Presentation (April 2024)Investor deck42 slidesApr 10, 2024
Investor Presentation (February 2024)Investor deck40 slidesFeb 22, 2024
Investor Presentation (January 2024)Investor deck33 slidesJan 9, 2024
Investor Presentation (December 2023)Investor deck33 slidesDec 21, 2023
Investor Presentation (September 2023)Investor deck25 slidesSep 12, 2023
Investor Presentation (June 2023)Investor deck34 slidesJun 8, 2023
Investor Presentation (April 2023)Investor deck33 slidesApr 20, 2023
Investor Presentation (March 2023)Investor deck27 slidesMar 20, 2023
Investor Presentation (November 2022)Investor deck34 slidesNov 29, 2022
All 18 decks
DeckKindSlidesDate
Investor Presentation (November 2022)Investor deck36 slidesNov 3, 2022
Investor Presentation (August 2022)Investor deck30 slidesAug 9, 2022
Investor Presentation (July 2022)Investor deck31 slidesJul 5, 2022
Investor Presentation (June 2022)Investor deck29 slidesJun 7, 2022
Investor Presentation (May 2022)Investor deck29 slidesMay 2, 2022
Investor Presentation (March 2022)Investor deck28 slidesMar 15, 2022
Investor Presentation (February 2022)Investor deck28 slidesFeb 15, 2022
IPO Roadshow (November 2021)IPO roadshow28 slidesNov 10, 2021

Open Decks

Financings

RaiseDate
Private placement of ordinary shares
Announced: US$600,000 · US$0.8 a share
Buyers: Alon Ben-Noon ($200,000); Or Eisenberg ($200,000)
Insiders: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000
Use of proceeds: General corporate purposes ahead of upcoming clinical and regulatory milestones
Apr 28, 2026
Private placement of ordinary shares
Announced: US$500,000 · US$1.5 a share
Use of proceeds: General corporate purposes and working capital
Sep 4, 2025
Private placement of ordinary shares (or ordinary share equivalents) and warrants
Closed: US$5M raised · US$1.25 a share · Warrants at US$1.25 for 60 months
Buyers: Alon Ben-Noon
Insiders: Chief Executive Officer Alon Ben-Noon entered into the definitive agreement to purchase in the private placement alongside a single investor
Use of proceeds: General corporate and working capital purposes
Dec 18, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$6.00 a unit on Dec 8, 2021.

Price
US$6.00 a unit
Units offered
2,000,000 units
Offering size
US$12 million
Underwriters' option
Up to 300,000 more units
Listing
NRSN on the Nasdaq Capital Market
Underwriter
Sole Book-Running Manager Maxim Group LLC
Units delivered
On or about Dec 13, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceAug 10, 2021
Filed publiclyOct 18, 2021
Amended 4 timesNewest Dec 6, 2021
Shares registered with an exchangeNov 18, 2021
Declared effective by the SECDec 8, 2021
Final prospectus, with the priceDec 10, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Dec 10, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue22.0K97.0K89.0K3.00K3.00K
Gross profit-22.0K-97.0K-89.0K-3.00K-3.00K
Research and development6.23M5.70M7.27M5.59M1.39M2.50M898.0K
Selling, general and administrative4.86M4.20M4.78M7.14M2.50M393.0K337.0K
Operating income-11.1M-9.90M-12.0M-10.6M-2.98M-2.89M-1.24M
Depreciation and amortization16.0K22.0K21.0K12.0K3.00K3.00K1.24M
EBITDA-11.1M-9.88M-12.0M-10.5M-2.98M-2.88M0
Interest expense311.0K550.0K15.0K1.15M1.00K5.00K
Income before tax-11.1M-10.2M-10.1M-12.3M-4.04M-2.83M-1.22M
Income tax-1-1.14M-1.55M1.00K5.00K
Net income-11.1M-10.2M-10.1M-10.5M-3.22M-2.83M-1.23M
Earnings per share, basic-0.44-0.54-0.74-0.91-0.52-10.25-4.50
Earnings per share, diluted-0.44-0.54-0.74-0.91-0.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents166.0K3.38M2.64M3.54M11.1M699.0K895.0K
Short-term investments03.55M0
Receivables33.0K164.0K166.0K131.0K178.0K30.0K18.0K
Inventory-3.68M-178.0K-67-18
Current assets778.0K4.40M2.92M7.38M11.4M729.0K913.0K
Property, plant and equipment58.0K66.0K85.0K77.0K19.0K13.0K7.00K
Total assets1.03M4.58M3.19M7.72M11.4M779.0K955.0K
Accounts payable799.0K1.16M1.46M498.0K39.0K55.0K23.0K
Current liabilities2.52M1.99M3.46M1.73M597.0K120.0K37.0K
Total debt170.0K73.0K142.0K211.0K1.83M
Total liabilities2.59M1.99M4.94M1.87M2.42M120.0K37.0K
Shareholders' equity-1.56M2.58M-1.76M5.84M10.8M659.0K918.0K
Shares outstanding32.6M23.2M15.4M11.8M23.2M275.9K272.7K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-7.67M-10.1M-8.35M-7.62M-1.54M-695.0K-582.0K
Capital spending-8.00K-3.00K-29.0K-70.0K-17.0K-9.00K-7.00K
Free cash flow-7.68M-10.1M-8.38M-7.69M-1.56M-704.0K-589.0K
Cash from investing-8.00K1.00K3.47M-3.59M-17.0K-9.00K-26.0K
Cash from financing4.43M10.9M3.98M3.77M11.9M508.0K1.42M
Change in cash-3.21M738.0K-903.0K-7.52M10.4M-196.0K809.0K

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 18, 2026Current reportSEC
6-K · Report of a foreign issuerNov 2, 2026Current reportSEC
6-K · Report of a foreign issuerOct 26, 2026Current reportSEC
6-K · Report of a foreign issuerOct 19, 2026Current reportSEC
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
6-K · Report of a foreign issuerOct 2, 2026Current reportSEC
6-K · Report of a foreign issuerSep 25, 2026Current reportSEC
6-K · Report of a foreign issuerSep 9, 2026Current reportSEC
6-K · Report of a foreign issuerAug 27, 2026Current reportSEC
6-K · Report of a foreign issuerAug 13, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerAug 6, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveAug 3, 2026Other filingsSEC
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
F-3/A · Registration statement, amendedJul 30, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 22, 2026Current reportSEC
6-K · Report of a foreign issuerJun 29, 2026Current reportSEC
6-K · Report of a foreign issuerJun 25, 2026Current reportSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 11, 2026Current reportSEC
6-K · Report of a foreign issuerJun 9, 2026Current reportSEC
6-K · Report of a foreign issuerJun 8, 2026Current reportSEC
6-K · Report of a foreign issuerApr 28, 2026Current reportSEC
6-K · Report of a foreign issuerApr 24, 2026Current reportSEC
6-K · Report of a foreign issuerApr 6, 2026Current reportSEC
6-K · Report of a foreign issuerApr 3, 2026Current reportSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 31, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 31, 2026Current reportSEC
20-F · Annual reportMar 31, 2026Annual reportSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 30, 2026Insider tradeSEC
4 · Change in ownershipMar 30, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 24, 2026Current reportSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
6-K · Report of a foreign issuerMar 11, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 18, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 13, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
F-3 · Registration statementJan 29, 2026Offer documentSEC
6-K · Report of a foreign issuerJan 6, 2026Current reportSEC
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
6-K · Report of a foreign issuerDec 8, 2025Current reportSEC
6-K · Report of a foreign issuerDec 4, 2025Current reportSEC
424B3 · ProspectusNov 26, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 26, 2025Other filingsSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
6-K · Report of a foreign issuerNov 24, 2025Current reportSEC
6-K · Report of a foreign issuerNov 21, 2025Current reportSEC
F-3 · Registration statementOct 28, 2025Offer documentSEC
6-K · Report of a foreign issuerOct 6, 2025Current reportSEC
6-K · Report of a foreign issuerSep 25, 2025Current reportSEC
6-K · Report of a foreign issuerSep 10, 2025Current reportSEC
6-K · Report of a foreign issuerSep 4, 2025Current reportSEC
6-K · Report of a foreign issuerSep 4, 2025Current reportSEC
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
6-K · Report of a foreign issuerAug 21, 2025Current reportSEC
6-K · Report of a foreign issuerAug 20, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveAug 19, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 19, 2025Other filingsSEC
S-8 · Registration statement for employee plansAug 15, 2025Offer documentSEC
POS AM · Amendment to an effective registrationAug 15, 2025Offer documentSEC
POS AM · Amendment to an effective registrationAug 15, 2025Offer documentSEC
424B5 · ProspectusAug 8, 2025Offer documentSEC
6-K · Report of a foreign issuerAug 1, 2025Current reportSEC
6-K · Report of a foreign issuerJul 10, 2025Current reportSEC
6-K · Report of a foreign issuerJun 26, 2025Current reportSEC
6-K · Report of a foreign issuerMay 7, 2025Current reportSEC
6-K · Report of a foreign issuerApr 24, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 17, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 17, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 11, 2025Offer documentSEC
POS AM · Amendment to an effective registrationApr 11, 2025Offer documentSEC
6-K · Report of a foreign issuerApr 7, 2025Current reportSEC
20-F · Annual reportApr 7, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 27, 2025Current reportSEC
6-K · Report of a foreign issuerMar 19, 2025Current reportSEC
424B5 · ProspectusFeb 21, 2025Offer documentSEC
6-K · Report of a foreign issuerFeb 19, 2025Current reportSEC
424B3 · ProspectusJan 17, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 17, 2025Other filingsSEC
CORRESP · Letter to the SECJan 16, 2025Other filingsSEC
6-K · Report of a foreign issuerJan 6, 2025Current reportSEC
CORRESP · Letter to the SECJan 6, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 3, 2025Other filingsSEC
F-3 · Registration statementDec 26, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 23, 2024Current reportSEC
6-K · Report of a foreign issuerDec 18, 2024Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveDec 13, 2024Other filingsSEC
424B3 · ProspectusDec 12, 2024Offer documentSEC
DDec 12, 2024Other filingsSEC
CORRESP · Letter to the SECDec 12, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 12, 2024Other filingsSEC
6-K · Report of a foreign issuerDec 11, 2024Current reportSEC
SC 13G · Big-stake noticeDec 9, 2024Big-stake noticeSEC
F-3 · Registration statementDec 6, 2024Offer documentSEC
6-K · Report of a foreign issuerDec 4, 2024Current reportSEC
6-K · Report of a foreign issuerDec 2, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
424B3 · ProspectusNov 22, 2024Offer documentSEC
CORRESP · Letter to the SECNov 21, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 21, 2024Other filingsSEC
F-1 · Registration statementNov 19, 2024Offer documentSEC
6-K · Report of a foreign issuerNov 12, 2024Current reportSEC
6-K · Report of a foreign issuerOct 31, 2024Current reportSEC
6-K · Report of a foreign issuerOct 30, 2024Current reportSEC
6-K · Report of a foreign issuerOct 28, 2024Current reportSEC
6-K · Report of a foreign issuerOct 24, 2024Current reportSEC
6-K · Report of a foreign issuerOct 15, 2024Current reportSEC
6-K · Report of a foreign issuerOct 9, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveOct 7, 2024Other filingsSEC
POS AM · Amendment to an effective registrationOct 1, 2024Offer documentSEC
6-K · Report of a foreign issuerSep 30, 2024Current reportSEC
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
6-K · Report of a foreign issuerSep 16, 2024Current reportSEC
6-K · Report of a foreign issuerSep 9, 2024Current reportSEC
6-K · Report of a foreign issuerAug 30, 2024Current reportSEC
6-K · Report of a foreign issuerAug 28, 2024Current reportSEC
6-K · Report of a foreign issuerAug 26, 2024Current reportSEC
6-K · Report of a foreign issuerAug 16, 2024Current reportSEC
424B5 · ProspectusAug 16, 2024Offer documentSEC
6-K · Report of a foreign issuerAug 7, 2024Current reportSEC
6-K · Report of a foreign issuerAug 1, 2024Current reportSEC
6-K · Report of a foreign issuerJul 9, 2024Current reportSEC
6-K · Report of a foreign issuerJul 3, 2024Current reportSEC
6-K · Report of a foreign issuerJul 1, 2024Current reportSEC
424B3 · ProspectusJun 27, 2024Offer documentSEC
424B3 · ProspectusJun 27, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 21, 2024Current reportSEC
424B3 · ProspectusJun 17, 2024Offer documentSEC
424B3 · ProspectusJun 17, 2024Offer documentSEC
6-K · Report of a foreign issuerJun 17, 2024Current reportSEC
6-K · Report of a foreign issuerMay 28, 2024Current reportSEC
6-K · Report of a foreign issuerMay 23, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 23, 2024Other filingsSEC
424B3 · ProspectusMay 22, 2024Offer documentSEC
CORRESP · Letter to the SECMay 21, 2024Other filingsSEC
F-1/A · Registration statement, amendedMay 20, 2024Offer documentSEC
6-K · Report of a foreign issuerMay 20, 2024Current reportSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
6-K · Report of a foreign issuerMay 14, 2024Current reportSEC
F-1 · Registration statementMay 10, 2024Offer documentSEC
6-K · Report of a foreign issuerMay 7, 2024Current reportSEC
DApr 25, 2024Other filingsSEC
424B5 · ProspectusApr 12, 2024Offer documentSEC
6-K · Report of a foreign issuerApr 12, 2024Current reportSEC
6-K · Report of a foreign issuerApr 10, 2024Current reportSEC
6-K · Report of a foreign issuerApr 9, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 9, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 9, 2024Other filingsSEC
6-K · Report of a foreign issuerApr 5, 2024Current reportSEC
POS AM · Amendment to an effective registrationApr 4, 2024Offer documentSEC
POS AM · Amendment to an effective registrationApr 4, 2024Offer documentSEC
20-F · Annual reportApr 4, 2024Annual reportSEC
6-K · Report of a foreign issuerFeb 22, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 7, 2024Current reportSEC
6-K · Report of a foreign issuerJan 9, 2024Current reportSEC
6-K · Report of a foreign issuerJan 9, 2024Current reportSEC
424B3 · ProspectusDec 27, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 27, 2023Current reportSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
424B3 · ProspectusDec 14, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 14, 2023Current reportSEC
424B3 · ProspectusDec 5, 2023Offer documentSEC
424B3 · ProspectusDec 5, 2023Offer documentSEC
6-K · Report of a foreign issuerDec 5, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveDec 5, 2023Other filingsSEC
CORRESP · Letter to the SECDec 4, 2023Other filingsSEC
POS AM · Amendment to an effective registrationDec 4, 2023Offer documentSEC
6-K · Report of a foreign issuerNov 28, 2023Current reportSEC
POS AM · Amendment to an effective registrationNov 21, 2023Offer documentSEC
6-K · Report of a foreign issuerNov 13, 2023Current reportSEC
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
6-K · Report of a foreign issuerOct 17, 2023Current reportSEC
6-K · Report of a foreign issuerOct 4, 2023Current reportSEC
6-K · Report of a foreign issuerOct 2, 2023Current reportSEC
6-K · Report of a foreign issuerSep 29, 2023Current reportSEC
6-K · Report of a foreign issuerSep 20, 2023Current reportSEC
6-K · Report of a foreign issuerSep 19, 2023Current reportSEC
6-K · Report of a foreign issuerSep 12, 2023Current reportSEC
424B3 · ProspectusSep 7, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 6, 2023Other filingsSEC
CORRESP · Letter to the SECAug 31, 2023Other filingsSEC
F-1/A · Registration statement, amendedAug 31, 2023Offer documentSEC
6-K · Report of a foreign issuerAug 16, 2023Current reportSEC
CORRESP · Letter to the SECAug 14, 2023Other filingsSEC

This page holds 200 of 315 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from NeuroSense Therapeutics Ltd.’s releases · as of Apr 28, 2026

Common shares
1,896,902
Fully diluted
1,896,902

Fully diluted

LineShares
Common shares1,896,902

Warrants and options

Lot
Warrants · US$1.25 · expire about Dec 2029

Share count over time

CountShares
Nov 22, 20261,896,902

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
Fidelity Nasdaq Composite Index Fund15,870US$13,036May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Eisenberg Or
Officer: Chief Financial Officer
Buy250,000USD 0.80US$200KJun 16, 2026
Ben-Noon Alon
Officer: Chief Executive Officer
Buy250,000USD 0.80US$200KJun 16, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cary Claiborne
Other companies: Adial Pharmaceuticals, Inc (Chief Executive Officer, Director · Since at least Apr 7, 2026); Azora Therapeutics, Inc. (Chief Executive Officer, Director · Since at least May 29, 2025)
Board Member · Since at least Mar 18, 2026
Roy Golan
Other companies: MySize, Inc. (Director · Since at least Mar 6, 2025); Ayala Pharmaceuticals Inc (Chief Financial Officer · Oct 18, 2023 – Oct 18, 2023 · Past)
Board Member · Since at least Mar 18, 2026
Or Eisenberg
Other companies: Big Digital Energy, Inc. (CFO and Secretary · Nov 16, 2017 – Mar 9, 2021 · Past)
Chief Financial Officer · Since at least Mar 18, 2026
Alon Ben-NoonCEO & Board Member · Since at least Jun 17, 2026
Christine PellizzariBoard Member · Since at least Nov 5, 2026
Ferenc TracikChief Medical Officer · Since at least Mar 18, 2026
Hagit BinderGeneral Manager · Since at least Nov 21, 2024
Mark LeuchtenbergerChairman of the board · Since at least Nov 5, 2026
Niva Russek-BlumChief Technology Officer · Since at least Mar 18, 2026
Revital Mandil-LevinBoard Member · Since at least Mar 18, 2026
All 11 people
PersonSeat
Shiran ZimriVP R&D | Country Lead, Canada · Since at least Oct 29, 2026

Open People

Log in to ask 6ix AI your own questions about NeuroSense Therapeutics Ltd.